✦ LIBER ✦

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

✍ Scribed by Robert J. Amato; Jaroslaw Jac; Sarah Giessinger; Somyata Saxena; James P. Willis

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 184 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24280

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study of the oral mammalian ta

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

✍ Brian M. Slomovitz; Karen H. Lu; Taren Johnston; Robert L. Coleman; Mark Munsell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA, are the most common mutations in endometrial carcinoma (EC). Loss of PTEN or activation of PIK3CA results in cons

A phase 2 study of a fixed combination o

A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer

✍ Gabriel N. Hortobagyi; Robyn R. Young; Mark Karwal; Nuhad K. Ibrahim; Robert Her 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

A phase 2 study of a fixed combination o

A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer

✍ Gabriel N. Hortobagyi; William Heim; Laura Hutchins; Edgardo Rivera; Bernard Mas 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

A population-based study evaluating the

A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

✍ Daniel Y. C. Heng; Kim N Chi; Nevin Murray; Tao Jin; Jorge A Garcia; Ronald M Bu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 1 views

## Abstract ## BACKGROUND: Sunitinib has replaced interferon (IFN) as a first‐line standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. ## METH

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin

A phase II study of the safety and effic

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

✍ Leena Gandhi; Matthew W. Harding; Marcus Neubauer; Corey J. Langer; Melvin Moore 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views